Table 2.

Clinical probability, cost and utility inputs

Description	Base value	Range	Distribution	Ref.
Treatment success from initial, VAN	0.857	0.771–0.943	Beta	[3,4]
Treatment success from initial, FDX	0.876	0.788–0.963	Beta	[3,4]
Treatment success from initial, BEZ	0.859	0.773–0.945	Beta	[5]
Treatment success from initial, EPFX	0.819	0.737–0.900	Beta	[8]
Treatment success from recurrence, VAN	0.889	0.800–0.978	Beta	[3,4]
Treatment success from recurrence, FDX	0.898	0.808–0.988	Beta	[3,4]
Treatment success from recurrence, BEZ	0.859	0.773–0.945	Beta	[5]
Treatment success from recurrence, EPFX	0.819	0.737–0.900	Beta	[8]
First recurrence, VAN	0.248	0.198–0.297	Beta	[3,4]
First recurrence, FDX	0.129	0.10–0.155	Beta	[3,4]
First recurrence, BEZ	0.160	0.128–0.192	Beta	[5]
First recurrence, EPFX	0.078	0.062–0.093	Beta	[8]
Second recurrence, VAN	0.325	0.260–0.390	Beta	[3,4]
Second recurrence, FDX	0.203	0.162–0.243	Beta	[3,4]
Second recurrence, BEZ	0.198	0.158–0.237	Beta	[5]
Second recurrence, EPFX	0.122	0.098–0.146	Beta	[8]
Third recurrence	0.45	0.25–0.65	Beta	[18]
Colectomy	0.015	0.012–0.018	Beta	N/A a
Post–colectomy	0.584	0.467–0.701	Beta	[17]
Sustained clinical cure from initial, VAN	0.646	0.517–0.775	Beta	[3,4] e
Sustained clinical cure from initial, FDX	0.758	0.606–0.910	Beta	[3,4] e
Sustained clinical cure from initial, BEZ	0.646	0.517–0.775	Beta	N/A b,e
Sustained clinical cure from initial, EPFX	0.758	0.606–0.910	Beta	N/A c,e
Attributable CDI mortality	0.026	0.021–0.031	Beta	[19]
Background mortality, year 0	0.010	0.008–0.012	Beta	[20] e
Background mortality, year 1	0.011	0.009–0.013	Beta
Background mortality, year 2	0.012	0.009–0.014	Beta
Vancomycin cost	$21	$17–$26	N/A d	[24]
Standard fidaxomicin cost	$3613	$2890–$4335		[24]
Extended-pulsed fidaxomicin cost	$3613	$2890–$4335		[24]
Bezlotoxumab cost	$3896	$3117–$4675		[15,23,24]
Bezlotoxumab infusion time (h)	1	0.8–1.2	Gamma	[15]
CDI outpatient visit time (h)	2	1.6–2.4	Gamma	N/A a
Initial attributable cost	$28 952	$28 032–$29 919	Gamma	[25]
Initial cumulative hospitalization (days)	5.2	5.01–5.39	Gamma	[25]
Recurrent attributable cost	$12 655	$10 584– $14,887	Gamma	[25]
Recurrent cumulative hospitalization (days)	1.95	1.48–2.43	Gamma	[25]
Colectomy cost	$43 156	$24 548–$49 095	Gamma	[17]
Post-colectomy annual cost	$10 883	$0–$24 464	Gamma	[26]
Baseline utility	0.88	0.7–1.00	Beta	[3,4,28]
Disease utility	0.76	0.61 –0.91	Beta	[10,28]
Colectomy utility	0.72	0.58–0.86	Beta	[10,28]
Post-colectomy utility	0.39	0.31–0.46	Beta	[12,29,30]

Abbreviations: BEZ, bezlotoxumab plus vancomycin; EPFX, extended-pulsed fidaxomicin; FDX, standard fidaxomicin; VAN, vancomycin.

^aClinician Estimates.

^bAssumed to be the same as vancomycin.

^cAssumed to be the same as standard fidaxomicin.

^dNot included in probabilistic sensitivity analyses.

^eFurther are shown in Technical Appendix Table 1.